Preferred Label : upadacitinib;
CISMeF synonym : ABT-494;
MeSH synonym : (3S,4R)-3-ethyl-4-(3H-imidazo(1,2-a)pyrrolo(2,3-e)pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-1-pyrrolidinecarboxamide;
UNII : 4RA0KN46E0;
Origin ID : C000613732;
UMLS CUI : C4726929;
ATC code(s)
Currated CISMeF NLP mapping
MeSH term(s) associated for indexing
Pharmacological action(s)
Record concept(s)
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
https://www.has-sante.fr/jcms/p_3479047/fr/rinvoq-upadacitinib-maladie-de-crohn-active-moderee-a-severe-chez-les-patients-adultes
2023
false
false
false
France
treatment outcome
Delayed-Action preparations
upadacitinib
Janus Kinase Inhibitors
insurance, health, reimbursement
evaluation of the transparency committee
crohn disease
adult
upadacitinib
---
https://ansm.sante.fr/tableau-marr/upadacitinib
2023
false
false
false
France
French
risk management
upadacitinib
patient education handout
guidelines for drug use
upadacitinib
Drug-Related side effects and adverse reactions
administration, oral
upadacitinib
Janus Kinase Inhibitors
Janus Kinase Inhibitors
teratogens
pregnancy
continuity of patient care
herpes zoster
tuberculosis
neoplasms
embolism and thrombosis
Virus Reactivation
---
https://www.has-sante.fr/jcms/p_3313562/fr/rinvoq-upadacitinib-hemihydrate-dermatite-atopique
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, oral
adult
adolescent
upadacitinib
evaluation of the transparency committee
upadacitinib
dermatitis, atopic
---
https://www.has-sante.fr/jcms/p_3392764/fr/rinvoq-upadacitinib-hemihydrate-spondyloarthrite-axiale-non-radiographique
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
upadacitinib
adult
administration, oral
Delayed-Action preparations
antirheumatic agents
Janus Kinase Inhibitors
evaluation of the transparency committee
Non-Radiographic Axial Spondyloarthritis
upadacitinib
---
https://www.has-sante.fr/jcms/p_3271030/fr/rinvoq-upadacitinib-rhumatisme-psoriasique
2021
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
arthritis, psoriatic
administration, oral
upadacitinib
antirheumatic agents
upadacitinib
adult
Janus Kinase Inhibitors
---
https://www.has-sante.fr/jcms/p_3271030
2021
France
evaluation of the transparency committee
arthritis, psoriatic
Rinvoq
rheumatic diseases
upadacitinib
psoriasis
Psoriatic arthritis
psoriasis with arthropathy
upadacitinib
---
https://www.has-sante.fr/jcms/p_3266947/fr/rinvoq-upadacitinib-spondylarthrite-ankylosante
2021
false
false
false
France
insurance, health, reimbursement
treatment outcome
administration, oral
upadacitinib
spondylitis, ankylosing
adult
Delayed-Action preparations
antirheumatic agents
evaluation of the transparency committee
upadacitinib
heterocyclic compounds, 3-ring
---
https://ansm.sante.fr/tableau-atu-rtu/upadacitinib-15-mg-et-30-mg-comprime-a-liberation-prolongee
2021
false
false
false
France
French
guidelines for drug use
summary of product characteristics
package leaflet
upadacitinib
upadacitinib
administration, oral
Delayed-Action preparations
upadacitinib
adult
adolescent
dermatitis, atopic
Janus Kinase Inhibitors
Janus Kinase Inhibitors
heterocyclic compounds, 3-ring
heterocyclic compounds, 3-ring
---
https://www.has-sante.fr/jcms/p_3302051/fr/rinvoq-upadacitinib-dermatite-atopique
https://www.has-sante.fr/jcms/p_3302088/fr/decision-n-2021-0300/dc/sem-du-25-novembre-2021-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-rinvoq
2021
false
false
false
France
dermatitis, atopic
treatment outcome
adult
adolescent
upadacitinib
upadacitinib
administration, oral
Janus Kinase Inhibitors
upadacitinib
guidelines for drug use
continuity of patient care
evaluation of the transparency committee
---
https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
upadacitinib
upadacitinib
upadacitinib
adult
arthritis, rheumatoid
drug therapy, combination
antirheumatic agents
antirheumatic agents
administration, oral
Janus Kinase Inhibitors
Janus Kinase Inhibitors
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
arthritis, psoriatic
spondylitis, ankylosing
heterocyclic compounds, 3-ring
heterocyclic compounds, 3-ring
---
https://www.has-sante.fr/jcms/p_3181658/fr/rinvoq
2020
false
false
false
France
treatment outcome
upadacitinib
upadacitinib
administration, oral
upadacitinib
insurance, health, reimbursement
antirheumatic agents
antirheumatic agents
adult
arthritis, rheumatoid
drug therapy, combination
Janus Kinase Inhibitors
Janus Kinase Inhibitors
evaluation of the transparency committee
heterocyclic compounds, 3-ring
heterocyclic compounds, 3-ring
---